Howard Weisman

EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products.

YourBio Health, Inc. develops health monitoring products. It is developing an array of products based on the company's proprietary TAP? (Touch Activated Phlebotomy) painless blood collection platform. The company was founded by Richard Rox Anderson, Joerg Lahann, Robert S. Langer Jr., Douglas A. Levinson and Samir Mitragotri in 2008 and is headquartered in Medford, MA.

EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products.

ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ

ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ

ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products.

YourBio Health, Inc. develops health monitoring products. It is developing an array of products based on the company's proprietary TAP? (Touch Activated Phlebotomy) painless blood collection platform. The company was founded by Richard Rox Anderson, Joerg Lahann, Robert S. Langer Jr., Douglas A. Levinson and Samir Mitragotri in 2008 and is headquartered in Medford, MA.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ

EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products.

ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ